BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) Based Therapies

BlueRock Therapeutics LP and bit.bio announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived Tregs for use in creating therapeutics. The collaboration leverages bit.bio’s machine learning-powered platform to identify transcription factor combinations for reprogramming iPSCs into Tregs.